Sonoma Pharmaceuticals, Inc. (SNOA)

Market Cap	2.55M
Revenue (ttm)	12.31M
Net Income (ttm)	-5.08M
Shares Out	15.61M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,382
Open	0.165
Previous Close	0.161
Day's Range	0.161 - 0.166
52-Week Range	0.120 - 1.520
Beta	1.29
Analysts	Strong Buy
Price Target	3.25 (+1,912.38%)
Earnings Date	Feb 8, 2024

About SNOA

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 25, 2007
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: SNOA

Financial Performance

In 2022, SNOA's revenue was $13.27 million, an increase of 5.10% compared to the previous year's $12.63 million. Losses were -$5.15 million, 1.28% more than in 2021.

Analyst Forecast

According to one analyst, the rating for SNOA stock is "Strong Buy" and the 12-month stock price forecast is $3.25.

Price Target

$3.25

(1,912.38% upside)

Analyst Consensus: Strong Buy